A Subcutaneous TKI for the Treatment of Neovascular AMD and Diabetic Retinopathy
Retina Synthesis
0:00 / 0:00
A Subcutaneous TKI for the Treatment of Neovascular AMD and Diabetic Retinopathy
8 просмотров · 1 день назад
Retina Synthesis
219 подписчиков
8 просмотров · 1 день назад
In this episode we discuss the use of a subcutaneously administered tyrosine kinase inhibitor migaldendranib (D-4517.2) or MGB for the treatment of neovascular AMD and diabetic macular edema.
